PTC Therapeutics Inc (PTCT) Insider Trading
- $31,673,582.00
- $173,198,187.08
- Feb. 18, 2026
- Mark Elliott Boulding
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Feb. 18, 2026 | EVP | 2,484 | $69.36 | Sell | $172,290.24 | |
| Feb. 18, 2026 | CEO | 7,371 | $69.36 | Sell | $511,252.56 | |
| Feb. 18, 2026 | Insider | 3,056 | $69.36 | Sell | $211,964.16 | |
| Feb. 18, 2026 | CAO | 2,494 | $69.36 | Sell | $172,983.84 | |
| Feb. 18, 2026 | VP | 3,081 | $69.36 | Sell | $213,698.16 | |
| Feb. 18, 2026 | CFO | 2,992 | $69.36 | Sell | $207,525.12 | |
| Feb. 18, 2026 | Insider | 3,019 | $69.36 | Sell | $209,397.84 | |
| Feb. 17, 2026 | VP | 2,813 | $69.29 | Sell | $194,912.77 | |
| Sept. 12, 2025 | VP | 24,585 | $61.34 | Sell | $1,508,043.90 | |
| Sept. 11, 2025 | Director | 15,705 | $59.50 | Sell | $934,447.50 | |
| Sept. 11, 2025 | VP | 22,664 | $61.00 | Sell | $1,382,504.00 | |
| Sept. 9, 2025 | Director | 12,000 | $58.34 | Sell | $700,080.00 | |
| Sept. 8, 2025 | Insider | 39,850 | $56.92 | Sell | $2,268,262.00 | |
| Aug. 28, 2025 | Director | 1,667 | $50.15 | Sell | $83,600.05 | |
| Aug. 5, 2025 | CEO | 10,739 | $51.74 | Sell | $555,635.86 | |
| July 15, 2025 | CFO | 2,516 | $49.46 | Sell | $124,441.36 | |
| May 16, 2025 | VP | 883 | $46.02 | Sell | $40,635.66 | |
| May 15, 2025 | VP | 1,929 | $46.18 | Sell | $89,081.22 | |
| April 22, 2025 | CEO | 2,804 | $48.74 | Sell | $136,666.96 | |
| April 2, 2025 | EVP | 897 | $46.95 | Sell | $42,114.15 | |
| March 13, 2025 | Director | 5,000 | $54.00 | Sell | $270,000.00 | |
| March 12, 2025 | VP | 15,521 | $53.30 | Sell | $827,269.30 | |
| March 4, 2025 | Director | 1,230 | $51.52 | Sell | $63,369.60 | |
| Feb. 19, 2025 | EVP | 795 | $50.10 | Sell | $39,829.50 | |
| Feb. 19, 2025 | CFO | 1,168 | $50.10 | Sell | $58,516.80 | |
| Feb. 19, 2025 | VP | 1,333 | $50.10 | Sell | $66,783.30 | |
| Feb. 19, 2025 | CEO | 1,378 | $50.10 | Sell | $69,037.80 | |
| Feb. 19, 2025 | CAO | 879 | $50.10 | Sell | $44,037.90 | |
| Feb. 19, 2025 | Insider | 1,300 | $50.10 | Sell | $65,130.00 | |
| Jan. 7, 2025 | Insider | 1,265 | $45.34 | Sell | $57,355.10 | |
| Jan. 7, 2025 | EVP | 810 | $45.34 | Sell | $36,725.40 | |
| Jan. 7, 2025 | VP | 1,543 | $45.34 | Sell | $69,959.62 | |
| Jan. 7, 2025 | CEO | 1,599 | $45.34 | Sell | $72,498.66 | |
| Jan. 7, 2025 | CAO | 1,291 | $45.34 | Sell | $58,533.94 | |
| Dec. 31, 2024 | CEO | 8,279 | $45.16 | Sell | $373,879.64 | |
| Dec. 2, 2024 | Insider | 69,550 | $52.06 | Sell | $3,620,773.00 | |
| Dec. 2, 2024 | VP | 85,600 | $52.26 | Sell | $4,473,456.00 | |
| Dec. 2, 2024 | CAO | 17,800 | $51.77 | Sell | $921,506.00 | |
| Dec. 2, 2024 | Director | 24,000 | $51.50 | Sell | $1,236,000.00 | |
| July 16, 2024 | CFO | 2,269 | $34.02 | Sell | $77,191.38 | |
| May 22, 2024 | Director | 20,000 | $38.24 | Sell | $764,800.00 | |
| May 7, 2024 | EVP | 175 | $32.82 | Sell | $5,743.50 | |
| April 19, 2024 | CEO | 3,361 | $24.89 | Sell | $83,655.29 | |
| April 17, 2024 | CEO | 787 | $25.14 | Sell | $19,785.18 | |
| April 2, 2024 | EVP | 526 | $28.37 | Sell | $14,922.62 | |
| Jan. 30, 2024 | Insider | 618 | $27.25 | Sell | $16,840.50 | |
| Jan. 30, 2024 | CAO | 318 | $27.25 | Sell | $8,665.50 | |
| Jan. 30, 2024 | VP | 794 | $27.25 | Sell | $21,636.50 | |
| Jan. 22, 2024 | Director | 10,000 | $27.38 | Sell | $273,800.00 | |
| Jan. 8, 2024 | Insider | 1,569 | $28.64 | Sell | $44,936.16 |
Insiders are both buying and selling PTC Therapeutics Inc stock.
The insider traders at PTC Therapeutics Inc are: Mark Elliott Boulding, Stuart Walter Peltz, Christine Marie Utter, Neil Gregory Almstead, Emily Luisa Hill, Eric Pauwels, Matthew B Klein, Allan Steven Jacobson, Mark Rothera, David P Southwell, Claudia De Oliveira Ri Hirawat, Lee Scott Golden, Pierre Gravier, Marcio Souza, Stephanie Okey, Dawn Svoronos, Emma Reeve, Hbm Healthcare Investments (Ca, Jerome B Zeldis, Michael Schmertzler, Shane William Charles Kovacs, Alethia Young, Matthew B. Klein, Adam Koppel, Richard Aldrich, Robert J Spiegel, Robert Spiegel, David Southwell, Michael Kranda, and Michael L Kranda
The most active insider trader at PTC Therapeutics Inc is Mark Elliott Boulding with 33 trades.
Stuart Walter Peltz has sold the most PTC Therapeutics Inc stock with a total value of $85,044,720.20.
Adam Koppel has bought the most PTC Therapeutics Inc stock with a total value of $37,500,000.00.
The most recent insider trade for PTC Therapeutics Inc was on Feb. 18, 2026.
The single biggest insider buy for PTC Therapeutics Inc was from Adam Koppel with a total value of $18,750,000.00 on June 25, 2013.
The single biggest insider sell for PTC Therapeutics Inc was from Stuart Walter Peltz with a total value of $21,253,437.00 on Dec. 7, 2020.
